ID   ClearCa-5
AC   CVCL_X574
SY   clearCa-5
DR   IARC_TP53; 23210
DR   Wikidata; Q54813625
RX   CelloPub=CLPUB00407;
RX   CelloPub=CLPUB00411;
RX   PubMed=9146668;
RX   PubMed=10737390;
RX   PubMed=11139287;
RX   PubMed=15863265;
CC   Doubling time: 32 hours (PubMed=9146668).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; c.952_966del15; Zygosity=Unspecified (PubMed=15863265).
DI   NCIt; C4033; Clear cell renal cell carcinoma
DI   ORDO; Orphanet_319276; Clear cell renal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 05-09-14; Last updated: 19-12-24; Version: 9
//
RX   CelloPub=CLPUB00407;
RA   Krieg A.;
RT   "Characterization and functional analysis of the TRAIL system and
RT   the inhibitor of apoptosis protein (IAP) family in human neoplasia.";
RL   Thesis MD (2005); Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany.
//
RX   CelloPub=CLPUB00411;
RA   Petek O.;
RT   "Analysis of expression and mutation of the antimetastatic gene NM23 in
RT   human renal carcinoma cell lines and epithelioid sarcomas.";
RL   Thesis MD (2002); Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany.
//
RX   PubMed=9146668; DOI=10.1016/S0022-5347(01)64778-5;
RA   Ramp U., Jaquet K., Reinecke P., Schardt C., Friebe-Hoffmann U.,
RA   Nitsch T., Marx N., Gabbert H.E., Gerharz C.-D.;
RT   "Functional intactness of stimulatory and inhibitory autocrine loops
RT   in human renal carcinoma cell lines of the clear cell type.";
RL   J. Urol. 157:2345-2350(1997).
//
RX   PubMed=10737390; DOI=10.1054/bjoc.1999.1043; PMCID=PMC2374431;
RA   Engers R., Mrzyk S., Springer E., Fabbro D., Weissgerber G.,
RA   Gerharz C.-D., Gabbert H.E.;
RT   "Protein kinase C in human renal cell carcinomas: role in invasion and
RT   differential isoenzyme expression.";
RL   Br. J. Cancer 82:1063-1069(2000).
//
RX   PubMed=11139287; DOI=10.1038/sj.cdd.4400746;
RA   Dejosez M., Ramp U., Mahotka C., Krieg A., Walczak H., Gabbert H.E.,
RA   Gerharz C.-D.;
RT   "Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell
RT   carcinomas and its enhancement by topotecan.";
RL   Cell Death Differ. 7:1127-1136(2000).
//
RX   PubMed=15863265; DOI=10.1016/j.canlet.2004.09.045;
RA   Reinecke P., Kalinski T., Mahotka C., Schmitz M., Dejosez M.,
RA   Gabbert H.E., Gerharz C.-D.;
RT   "Paclitaxel/taxol sensitivity in human renal cell carcinoma is not
RT   determined by the p53 status.";
RL   Cancer Lett. 222:165-171(2005).
//